Daquiran

RSS

pramipexole

Withdrawn
This medicine is now withdrawn from use in the European Union.

Overview

The marketing authorisation for Daquiran has been withdrawn at the request of the marketing authorisation holder.

This EPAR was last updated on 22/05/2006

Authorisation details

Product details
Name
Daquiran
Agency product number
EMEA/H/C/000135
Active substance
pramipexole dihydrochloride monohydrate
International non-proprietary name (INN) or common name
pramipexole
Therapeutic area (MeSH)
Parkinson Disease
Anatomical therapeutic chemical (ATC) code
N04BC05
Publication details
Marketing-authorisation holder
Dr. Karl Thomae GmbH
Revision
5
Date of issue of marketing authorisation valid throughout the European Union
26/10/1997
Contact address
Birkendorfferstr. 65
D-88397 Biberach/Riss
Germany

Product information

01/02/2006 Daquiran - EMEA/H/C/000135 -

Contents

  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Anti Parkinson drugs

Therapeutic indication

DAQUIRAN tablets are indicated for treatment of the signs and symptoms of advanced idiopathic Parkinson's disease in combination with levodopa, i.e. over the course of the disease, when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end of dose or "on off" fluctuations).

How useful was this page?

Add your rating